Repro Med Systems Inc Total Assets
Repro Med Systems Inc total assets. Based on the latest financial reports, Repro Med Systems Inc (KRMD) holds total assets worth $27.96 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Repro Med Systems Inc (KRMD) total market value for the company's overall valuation and market capitalisation.
Total Assets of Repro Med Systems Inc (1996–2025)
Total assets of Repro Med Systems Inc from 1996 to 2025. This chart illustrates how Repro Med Systems Inc's total assets have evolved over time, based on quarterly financial data. See Repro Med Systems Inc share price for real-time trading data and today's change.
Repro Med Systems Inc - Asset Composition Analysis
Repro Med Systems Inc Total Assets Breakdown (December 2025)
Repro Med Systems Inc total assets breakdown as of December 2025. Repro Med Systems Inc's total assets of $27.96 Million consist of 70.9% current assets and 29.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 31.5% |
| Accounts Receivable | $6.53 Million | 23.2% |
| Inventory | $3.68 Million | 13.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $684.84K | 2.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Repro Med Systems Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore KRMD working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Repro Med Systems Inc's current assets represent 70.9% of total assets in 2025, an increase from 49.0% in 1996.
- Cash Position: Cash and equivalents constituted 31.5% of total assets in 2025, up from 3.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 23.2% of total assets.
Repro Med Systems Inc Competitors by Total Assets
Key competitors of Repro Med Systems Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Caina Technology Co. Ltd.
SHE:301122
|
China | CN¥2.26 Billion |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
Ocumetics Technology Corp
V:OTC
|
Canada | CA$1.15 Million |
|
Osteopore Ltd
AU:OSX
|
Australia | AU$2.77 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.39 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
Repro Med Systems Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.72 | 2.91 | 8.26 |
| Quick Ratio | 2.09 | 2.25 | 6.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.33 Million | $11.53 Million | $33.10 Million |
Repro Med Systems Inc - Advanced Valuation Insights
This section examines the relationship between Repro Med Systems Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.70 |
| Latest Market Cap to Assets Ratio | 5.05 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | $28.20 Million |
| Market Capitalization | $142.39 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Repro Med Systems Inc's assets at a significant premium (5.05x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Repro Med Systems Inc's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Repro Med Systems Inc (1996–2025)
The table below shows the annual total assets of Repro Med Systems Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $28.20 Million | +3.61% |
| 2024-12-31 | $27.22 Million | -4.37% |
| 2023-12-31 | $28.46 Million | -32.77% |
| 2022-12-31 | $42.33 Million | +2.52% |
| 2021-12-31 | $41.29 Million | +3.44% |
| 2020-12-31 | $39.92 Million | +187.56% |
| 2019-12-31 | $13.88 Million | +31.64% |
| 2018-12-31 | $10.55 Million | +13.62% |
| 2017-12-31 | $9.28 Million | +13.59% |
| 2016-12-31 | $8.17 Million | -0.29% |
| 2015-12-31 | $8.19 Million | +12.53% |
| 2014-12-31 | $7.28 Million | +17.27% |
| 2013-12-31 | $6.21 Million | +11.02% |
| 2012-12-31 | $5.59 Million | +16.38% |
| 2011-12-31 | $4.81 Million | +55.82% |
| 2010-12-31 | $3.08 Million | +29.00% |
| 2009-12-31 | $2.39 Million | +3.47% |
| 2008-12-31 | $2.31 Million | +95.79% |
| 2007-12-31 | $1.18 Million | +3.66% |
| 2006-12-31 | $1.14 Million | +24.15% |
| 2005-12-31 | $916.99K | -9.47% |
| 2004-12-31 | $1.01 Million | -14.76% |
| 2003-12-31 | $1.19 Million | +6.98% |
| 2002-12-31 | $1.11 Million | -20.62% |
| 2001-12-31 | $1.40 Million | -3.07% |
| 2000-12-31 | $1.44 Million | -8.33% |
| 1999-12-31 | $1.57 Million | -32.13% |
| 1998-12-31 | $2.32 Million | -42.43% |
| 1997-12-31 | $4.03 Million | +20.30% |
| 1996-12-31 | $3.35 Million | -- |
About Repro Med Systems Inc
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropath… Read more